Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
18.63
+0.03 (0.16%)
At close: Apr 24, 2024, 4:00 PM
19.35
+0.72 (3.86%)
After-hours: Apr 24, 2024, 7:58 PM EDT
Myriad Genetics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Myriad Genetics stock have an average target of 22.5, with a low estimate of 14 and a high estimate of 31. The average target predicts an increase of 20.77% from the current stock price of 18.63.
Analyst Consensus: Buy
* Price targets were last updated on Jan 30, 2024.
Analyst Ratings
The average analyst rating for MYGN stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $31 | Strong Buy | Maintains | $28 → $31 | +66.40% | Jan 30, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $31 | Strong Buy | Maintains | $28 → $31 | +66.40% | Jan 29, 2024 |
| Piper Sandler | Piper Sandler | Hold Initiates $23 | Hold | Initiates | $23 | +23.46% | Dec 21, 2023 |
| Wells Fargo | Wells Fargo | Hold Initiates $20 | Hold | Initiates | $20 | +7.35% | Dec 19, 2023 |
| Guggenheim | Guggenheim | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +23.46% | Dec 14, 2023 |
Financial Forecast
Revenue This Year
843.21M
from 753.20M
Increased by 11.95%
Revenue Next Year
912.67M
from 843.21M
Increased by 8.24%
EPS This Year
0.02
from -3.18
EPS Next Year
0.25
from 0.02
Increased by 971.96%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 874.9M | 960.0M | 1.1B | 1.1B |
| Avg | 843.2M | 912.7M | 981.5M | 1.1B |
| Low | 794.0M | 843.0M | 895.7M | 1.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 16.2% | 13.9% | 15.7% | 12.9% |
| Avg | 12.0% | 8.2% | 7.5% | 9.7% |
| Low | 5.4% | -0.0% | -1.9% | 5.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 0.07 | 0.40 | 0.61 | 1.46 |
| Avg | 0.02 | 0.25 | 0.42 | 1.42 |
| Low | -0.02 | 0.03 | 0.09 | 1.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 1,635.5% | 147.1% | 251.1% |
| Avg | - | 972.0% | 68.7% | 241.1% |
| Low | - | 27.9% | -64.2% | 227.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.